Angiotensin II: Physiology and What Research Reports

What Angiotensin II Is

Angiotensin II is a short peptide hormone — eight amino acids long — that functions as the principal effector of the renin–angiotensin–aldosterone system (RAAS). Unlike hormones stored in secretory granules, it is generated on demand from a larger circulating precursor by two enzymatic steps, and it is then degraded within minutes. Because it is a peptide acting through G-protein-coupled receptors, angiotensin II appears across cardiovascular, renal, haematology and critical-care literature, and the term is often encountered by readers working through peptide and endocrine physiology. This page is for educational purposes only and is not medical advice; consult a licensed physician for any health decision.

Where Angiotensin II Is Produced

The pathway is usually described as a cascade rather than a single gland:

• Angiotensinogen — a precursor protein released largely by the liver into the circulation.
• Renin — an enzyme released by juxtaglomerular cells of the kidney in response to reduced perfusion, low sodium delivery or sympathetic signalling; it cleaves angiotensinogen to angiotensin I.
• Angiotensin-converting enzyme (ACE) — abundant on vascular endothelium, including the pulmonary circulation; it converts angiotensin I to angiotensin II.
• Local (tissue) systems — kidney, heart and vascular wall can generate angiotensin II locally, which is why much of the experimental literature studies organ-specific effects rather than circulating concentrations alone.

The liver's contribution to this cascade has been tested directly. A 2021 study in Circulation Research examined mice with deleted hepatic angiotensinogen, and researchers reported that loss of liver-derived angiotensinogen attenuated sepsis-induced myocardial dysfunction (PMID 34238019).

What Angiotensin II Does: Receptors and Target Tissues

Angiotensin II signals mainly through two receptor subtypes. AT1 receptors are associated in the literature with vasoconstriction, aldosterone release, sodium and water retention, thirst and growth or remodelling signalling. AT2 receptors are generally described as counter-regulatory. A 2022 review in Clinical Science focused on the AT2 receptor and reported a protective role for AT2 signalling in the glomerulus (PMID 36287192).

Kidney and glomerulus

The kidney is both a source and a target. A 2017 study in Kidney International investigated renal cortical cyclooxygenase-2 and reported an interaction between COX-2 and angiotensin II during postnatal nephrogenesis (PMID 28314575). In clinical nephrology, a 2024 review in Clinical and Experimental Nephrology discussed angiotensin II in the context of post-streptococcal glomerulonephritis (PMID 38170299).

Red blood cell production

Angiotensin II has also been linked to erythropoiesis. A 2021 paper in Molecules examined erythropoietin production and reported effects of angiotensin II on EPO production in the kidney and liver (PMID 34500833). A 2024 methods paper in MethodsX reported that angiotensin II promoted erythroid proliferation in a three-stage erythroid culture system (PMID 38660027).

Heart and fibrosis

Cardiac remodelling is one of the most studied downstream consequences. A 2023 study in Heliyon reported that insulin augmented angiotensin II-induced myocardial fibrosis via the MEK/STAT3 pathway (PMID 38125490), illustrating how metabolic signalling and angiotensin II signalling can intersect in experimental models.

How Angiotensin II Is Measured and Studied

Because circulating angiotensin II is short-lived and present at very low concentrations, laboratories typically combine several approaches rather than relying on a single measurement:

• Upstream surrogates — plasma renin activity or concentration, and angiotensinogen levels, are often used as indirect indicators of cascade activity.
• Direct quantification — immunoassays and mass-spectrometry-based peptide panels measure angiotensin peptides, usually with protease inhibitors added at collection.
• Genetic models — tissue-specific deletion isolates the contribution of one source, as in the hepatic angiotensinogen knockout work reported in 2021 (PMID 34238019).
• Cell and organ culture — defined-stage culture systems allow the peptide to be applied directly, as in the erythroid culture protocol whose authors reported pro-proliferative effects (PMID 38660027).
• Receptor pharmacology — AT1 and AT2 ligands are used to separate the two arms of signalling, an approach central to the glomerular AT2 review (PMID 36287192).

Angiotensin II in Critical-Care Literature

Angiotensin II is unusual among peptides in that a synthetic form exists as an approved intravenous product for raising blood pressure in adults with vasodilatory shock, which is why much of the human literature comes from intensive-care settings. A 2019 review in Critical Care Clinics summarised the rationale and evidence base for angiotensin II in vasodilatory shock (PMID 30784606), and a 2019 article in The American Journal of Emergency Medicine addressed its place in septic shock specifically (PMID 30935784). Smaller descriptive reports also exist: a 2021 case series in Critical Care Explorations described the use of angiotensin II in patients following near drowning (PMID 34046635).

Angiotensin II Safety and Open Questions: What Studies Report

The verified literature summarised here is largely mechanistic or narrative rather than an adverse-event tabulation, and it does not provide pooled safety rates. What it does report is uncertainty. A 2018 formulary-management review was titled to reflect exactly that, with the authors reporting that angiotensin II raised more questions than answers regarding its role and positioning in practice (PMID 30410284). A 2024 article in Medicina combined a literature review with real-life use observations of angiotensin II (PMID 39336524), and the 2019 septic-shock review likewise framed the evidence base as still developing (PMID 30935784). Readers looking for specific risk figures would need the full prescribing information and the primary trials, neither of which is summarised on this page.

Why the Term Matters to Peptide Readers

Angiotensin II is a useful reference point for three reasons. First, it demonstrates that a peptide of only eight residues can exert system-wide effects on vascular tone, sodium handling, red-cell production and tissue remodelling. Second, it shows how receptor subtype matters: the same peptide has been described as driving glomerular injury through one arm while AT2 signalling was reported as protective (PMID 36287192). Third, it is a reminder that peptides with genuine therapeutic use are usually studied for decades before clinical positioning is settled, as the 2024 review of real-life use and published evidence illustrated (PMID 39336524). Anyone meeting the term in a study abstract should note which receptor, which organ and which model the study used, because those details change the interpretation entirely.

References

• Loss of Hepatic Angiotensinogen Attenuates Sepsis-Induced Myocardial Dysfunction (Circulation Research, 2021)
• Angiotensin II in septic shock (The American Journal of Emergency Medicine, 2019)
• Angiotensin II and post-streptococcal glomerulonephritis (Clinical and Experimental Nephrology, 2024)
• Protecting glomerulus: role of angiotensin-II type 2 receptor (Clinical Science, 2022)
• Angiotensin II promotes erythroid proliferation in a three-stage erythroid culture system (MethodsX, 2024)
• Angiotensin II for Near Drowning: A Case Series (Critical Care Explorations, 2021)
• Effects of Angiotensin II on Erythropoietin Production in the Kidney and Liver (Molecules, 2021)
• Angiotensin II Brings More Questions Than Answers (P&T, 2018)
• Insulin augments angiotensin II-induced myocardial fibrosis via the MEK/STAT3 pathway (Heliyon, 2023)
• Angiotensin II in Vasodilatory Shock (Critical Care Clinics, 2019)
• Interaction of renal cortical cyclooxygenase-2 and angiotensin II in postnatal nephrogenesis (Kidney International, 2017)
• Angiotensin II-Real-Life Use and Literature Review (Medicina, 2024)